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Proton minibeam radiation therapy 
widens the therapeutic index for 
high-grade gliomas
Yolanda Prezado1, Gregory Jouvion2, Annalisa Patriarca3, Catherine Nauraye3, 
Consuelo Guardiola1, Marjorie Juchaux1, Charlotte Lamirault1, Dalila Labiod4,5, 
Laurene Jourdain6, Catherine Sebrie6, Remi Dendale3, Wilfredo Gonzalez1 & 
Frederic Pouzoulet4,5
Proton minibeam radiation therapy (pMBRT) is a novel strategy which has already shown a remarkable 
reduction in neurotoxicity as to compared with standard proton therapy. Here we report on the first 
evaluation of tumor control effectiveness in glioma bearing rats with highly spatially modulated proton 
beams. Whole brains (excluding the olfactory bulb) of Fischer 344 rats were irradiated. Four groups 
of animals were considered: a control group (RG2 tumor bearing rats), a second group of RG2 tumor-
bearing rats and a third group of normal rats that received pMBRT (70 Gy peak dose in one fraction) 
with very heterogeneous dose distributions, and a control group of normal rats. The tumor-bearing and 
normal animals were followed-up for 6 months and one year, respectively. pMBRT leads to a significant 
tumor control and tumor eradication in 22% of the cases. No substantial brain damage which confirms 
the widening of the therapeutic window for high-grade gliomas offered by pMBRT. Additionally, the 
fact that large areas of the brain can be irradiated with pMBRT without significant side effects, would 
allow facing the infiltrative nature of gliomas.
Radiotherapy (RT) has a key role in cancer treatment. In fact, about half of the patients will receive RT at some 
point during their illness1. The therapeutic use of ionizing radiation has been largely guided by the goal of directly 
eliminating all cancer cells while minimizing the toxicity to adjacent tissues2,3. Nowadays, technological advances 
in radiation delivery, including image guidance and particle therapy (i.e. proton therapy), have notably improved 
tumor dose conformation, thus reducing the dose to the organs-at-risk2,3. However, the treatment of some radi-
oresistant tumours, tumours close to a sensitive structure (e.g. central nervous system (CNS)) and pediatric can-
cers is still compromised due to the tolerances of normal tissues. However, the evolving wealth of biological 
knowledge4–10 allows seeking for new approaches. Indeed, the central dogma of conventional RT, namely that 
the cytotoxic effects of radiation are primarily due to the production of DNA double-strand breaks followed by 
some form of cell death (apoptosis, necrosis, autophagy, senescence), is being abandoned. This paradigm shift is 
led by the recent shreds of evidence of the importance of cell signaling7,8 and the role of the vascular9, stromal and 
immunological changes10 induced by the radiation in treatment outcome. The impact of those “non-targeted” 
effects on the biological response to radiation starts to be considered as a target itself to improve the therapeutic 
index in RT4–10.
Along this line, the utilization of distinct spatial distributions, such as in microbeam11 and minibeam radi-
ation therapy (MBRT)12,13, seems to activate different biological mechanisms from those involved when direct 
damage by ionizing radiation takes place. There are indications of the activation of the immune system14 and cell 
signaling effects15,16. Another player appears to be the preferential effect on the tumoral versus normal vascula-
ture. Normal tissues seem to benefit from the so-called microscopic prompt tissue-repair effect15,17, leading to a 
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fast repair of vascular damage. In contrast, tumors presented a denudation of capillaries accompanied by transient 
increase in permeability and a decrease in the number of tumor vessels17. MBRT uses a combination of spatial 
fractionation of the dose and submillimetric (500–700 μm) field sizes12,13: the irradiation is performed by using 
an array of parallel thin beams spaced by 1 to 3 mm. The dose profiles in MBRT consist of peaks and valleys in 
contrast to the flat profiles in standard RT. Low energy X-rays MBRT notably increases normal tissue resistance 
in animal experiments12,18–20, while delaying tumor growth21. However, the need of using short-penetrating kilo-
voltage beams (to maintain the peaks and valleys pattern) and the lack of a hospital-based facility currently limit 
possible patients’ treatments in the coming years.
To profit from the benefits of MBRT, we have recently proposed to explore the synergies of proton therapy 
and the spatial fractionation of the dose22. This novel therapeutic approach is called proton minibeam radiation 
therapy (pMBRT). Proton MBRT offers several advantages over x-rays MBRT. First, a negligible dose is deposited 
in normal tissues after the Bragg peak (tumour position), further reducing the secondary effects. In addition, the 
multiple Coulomb scattering of protons allows obtaining a homogeneous dose distribution in the tumour with 
only one array of proton minibeams22. This contrasts with x-rays MBRT, in which two orthogonal arrays need 
to be used, leading to a more complex and error prone irradiation geometry. Moreover, recent studies have evi-
denced distinct biological properties of protons23.
We implemented this technique at the Orsay proton therapy center in 201424. Dilmanian et al.25 confirmed 
the physical feasibility of the technique in 2015, in parallel to our first implementation24. A first study reporting 
on reduced side effects in the mouse ear after pMBRT with 20 MeV protons was published by a German team in 
201626. Even though the beam energy is not clinically relevant (a 20 MeV proton beam only penetrates 1 mm in 
the body), this work provided another indication of the advantages of this approach.
We have recently demonstrated that this technique notably increases the dose of tolerance of normal rat 
brain27. In a first experiment, the whole brain of two groups of normal rats was irradiated: i) a first group received 
a seamless (standard) proton irradiation, with high doses (25 Gy in one session); ii) a second group received 
pMBRT irradiation with peak doses of 58 Gy (corresponding to an average dose of 25 Gy). The animals were 
followed for up for 6 months. Rats treated with conventional proton irradiation exhibited severe moist desqua-
mation and substantial brain damage. In contrast, no significant damage was observed in the pMBRT group27. 
This finding may improve the therapeutic index in cases with good rates of tumor control but accompanied of 
substantial side effects. It also opens the door for a more efficient treatment of very radio-resistant tumors, such 
as high-grade gliomas (GBM), still one of the most challenging cases in clinical oncology. The goal of this work 
was to perform a first evaluation of gain in the therapeutic index provided by pMBRT in the treatment of gliomas 
with highly spatially modulated dose distributions.
Materials and Methods
All animal experiments were conducted in accordance with the animal welfare and ethical guidelines of our 
institutions. They were approved by the Ethics Committee of the Institut Curie and French Ministry of Research 
(permit no. 6361-201608101234488). Rats were anaesthetised with isoflurane (2.5% in air) during irradiation 
and magnetic resonance imaging (MRI). At the end of the study, the rats were terminally anaesthetised for brain 
fixation by the intracardiac perfusion of formalin zinc.
Tumor cell line and tumor implantation. A rat glioma cell line, RG2-[D74] (ATCC® CRL-2433™), was 
used. RG2 tumour model is known to be very aggressive in vivo, non-immunogeneic, with a highly invasive 
growth pattern, similar to human glioblastoma multiforme28. In particular, RG2 cells transfected with the lucif-
erase gene were used to perform Bioluminescence Imaging (BLI) at an IVIS spectrum (PerkerElmer). BLI offers 
a simple and rapid technique for assessing intracranial glioblastoma growth in rodent models noninvasively29–31 
and was therefore used to confirm the tumor presence before irradiation.
A number of 5000 RG2-Luc cells were suspended in 5 µl DMEM and then injected intracraneally into 19 Male 
Fischer 344 rats (Janvier Labs) using a Hamilton syringe through a burr hole in the right caudate nucleus (5 mm 
anterior to the ear-bars, i.e. at the bregma site, 3.0 mm lateral to the midline, and 5.5 mm depth from the skull). As 
average we have an implantation success rate of 97.8%.
For the BLI procedure the rats are injected intraperitoneally with a concentration of 150 mg/kgr (P/N 122799) 
of D-luceferin (Perkin Elmer) in 500 µl. The peak of luminescence is reached 25 minutes after injection. The pres-
ence of tumor is confirmed when the bioluminescent signal overcomes the background level. Thus, only the rats 
expressing a BLI signal significantly higher than the background on the day of the irradiation were included in the 
study. Table 1 shows the BLI signal values for those animals. The other rats were disregarded for further analysis.
Irradiations and dosimetry. The irradiations were performed at one of the horizontal beamlines (passive 
scattering) at the ICPO-Orsay with a proton beam energy of 100 MeV. This energy allows the treatment of a 
tumour located at the centre of the human brain (i.e., the worst scenario). This setup enabled the lateral irradia-
tion of rat brains in the plateau region. The dose rate was 2 Gy/min at a 1-cm depth.
For minibeam generation, a multislit brass collimator was employed (400-μm-wide slits, 3200-μm 
centre-to-centre distance24) and was positioned 7 cm away from the rat skin. With this configuration, the min-
ibeam width at a 1.0-cm depth was 1100 ± 50 μm. Further details of the experimental dosimetry in water phan-
toms can be found elsewhere24. Thus, large areas of the tumor received low doses (valley doses). Gafchromic films 
placed laterally on each side of the rat’s head (beam entry and exit) and attached to the skin allowed assessment 
of the quality of the irradiation.
Since the goal of this work was to evaluate the widening of the therapeutic window in pMBRT, two differ-
ent set of experiments were performed. The first one aimed at evaluating the tumour control effectiveness, thus 
tumour-bearing rats were irradiated and compared to controls. The second one was a long-term evaluation of 
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normal tissue toxicity, so normal rats (non-injected with any vehicle) were irradiated. Four groups of animals 
were considered: i) a control group (tumor bearing rats, non-irradiated) (n = 7); ii) a group of tumor bearing rats 
that received pMBRT 70 Gy peak dose at 1 cm depth, corresponding to an average of 30 Gy (n = 9). The irradia-
tions were performed 8 days after implantation. No comparison with conventional (seamless) PT has been per-
formed since such high mean doses would not be tolerated27. iii) a third group of normal (no-tumor implanted) 
rats (n = 9) that received pMBRT with the same dose and configuration than group ii); iv) a second control group 
of normal rats (n = 5). All the doses were delivered in one fraction to avoid any possible blurring inter-fraction of 
the minibeam pattern due to positioning errors.
In all four groups of animals, 7 weeks-old rats at the moment of irradiation were considered. This fits within 
the range of age used in the clear majority of rats’ studies (between 6 and 8 weeks after birth). The reason is that 
the incidence of successful development of the tumor after implantation is much superior than at older ages, 
probably related to a less developed immune system at the younger age32,33. To the best of our knowledge there are 
not data to be able to infer where the tumor response to treatment would differ if old rats are used. Additionally, 
this age (7 weeks-old) was also convenient to evaluate the side effects in the developing (more sensitive) brain at 
long-term.
To assess the dose distributions within the rats’ brains more precisely, Monte Carlo simulations (GATE v7.0) 
were employed. The whole proton beamline and the irradiation setting were modeled. Dose distributions were 
calculated in the computer tomography images of one of the representative rats, with a voxel scoring size of 
1 mm × 100 µm × 2 mm in the vertical, lateral and beam directions respectively. Figure 1 illustrates how the 
tumor was irradiated with a highly heterogeneous dose distribution. It shows a 2D map of the dose distributions 
Rat
BLI signal after background 
subtraction (p/s) Group
1 2,6 × 107 control
2 6,9 × 106 control
3 9,6 × 106 control
4 5,7 × 107 control
5 1,2 × 108 control
6 9,7 × 106 control
7 1,8 × 105 control
8 7,3 × 107 Irradiated
9 4,9 × 106 Irradiated
10 5,0 × 107 Irradiated
11 4,5 × 107 Irradiated
12 2,5 × 107 Irradiated
13 3,7 × 107 Irradiated
14 1,5 × 107 Irradiated
15 9,5 × 107 Irradiated
16 8,6 × 107 Irradiated
Table 1. BLI values for the rats included in the study.
Figure 1. Dosimetry. Left: 2D dose map in the rat head (coronal view). The red line marks the approximate 
position of the center of the tumor. Right: Corresponding lateral dose profile at the tumor position.
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inside a rat’s head (left) and lateral dose profile at the expected position of the tumor (right). The PVDR values 
amount 6.1 ± 0.2 and 6.5 ± 0.2 at the expected tumor position (center) and at the middle of the brain, respectively.
Animals follow up. The animals were followed-up for a maximum of 6 and 12 months in the case of 
tumour-bearing rats and normal rats, respectively. The clinical status of the animals was checked 5 and 2 times 
per week, in tumour bearing and normal rats, respectively. In the first case, any rat showing the classical adverse 
neurological signs related to the tumour growth in the brain was humanely killed. These signs could be any of 
the following: loss of appetite and substantial weight loss (>10% of the weight in 24 h), periorbital haemorrhages, 
seizures or prostration. To assess the survival curves, the median survival time post-implantation was calculated 
and Kaplan Meier survival data34 were plotted versus time after tumour implantation. The survival curves were 
compared using the log-rank test between the irradiated group and the controls (Prism-GraphPad).
In normal rats, the appearance of possible signs of distress was observed. Those include lack of grooming, 
hyperreactivity, apathy, spontaneous sound vocalizations, troubles of movement among others. In case of sus-
tained weight loss (>20% of the animal maximal weight), ataxia, prostration, troubles of movement, seizures or 
periorbital haemorrhages, the animals would be humanly killed.
An anatomical MRI study was performed at 6 months and one year after irradiation in 5 out the nine animals 
in the normal rats’ series. Additionally, a MRI evaluation was also carried out in five irradiated tumour-bearing 
rats at 10 days after irradiation and in all long-term survivals (6 months after irradiation). For each imaging 
session, a catheter was inserted into the tail vein for contrast agent administration. A 7-Tesla preclinical mag-
net (Bruker Avance Horizontal 7-T Bruker, Inc., Billerica, MA) equipped with a 35-mm-diameter “bird-cage” 
antenna was employed. Three series were acquired:
 i) Morphological T2-weighted (T2W) images with a repetition time (TR) of 2500 ms, an echo time (TE) of 
33 ms, an echo spacing 11 ms, rare factor 6 a signal average of 2. In all, 21 slices were acquired.
 ii) T1-weighted (T1W) TurboRare sequences with a TR of 800 ms and a TE of 6.05 m. A signal averaging of 2 
was employed. A total of 21 slides were acquired. Three acquisitions were performed, one before and two 
(1.3 and 8 min) after the intravenous injection of a bolus of 100 µmol/kg Gd-DOTA (Guerbet SA, Ville-
pinte, France).
 iii) T1 fast low-angle shot (FLASH) sequences with a TR and TE of 114.89 and 3.1 ms, respectively. A flip angle 
of 30° and a signal averaging of 4 were used. A total of 9 slides were acquired in a total time of 1 min 28 s. 
Acquisitions were made just before and immediately and 6.30 min after the intravenous injection of a bolus 
of 100 µmol/kg Gd-DOTA (Guerbet SA, Villepinte, France).
All experiments were acquired in axial orientation. The field of view was 35 mm × 35 mm, the in-plane res-
olution amounted to 0.137 mm × 0.137 mm, and the slice thickness and gap were 0.8 and 0.3 mm, respectively.
As explained before the tumor-bearing rats were sacrificed when the endpoints related to tumor growth were 
reached or, in their absence, at 6 months after irradiation. Irradiated normal rats were sacrificed 6 months (n = 5) 
and 12 months (n = 4) after irradiation and compared to control rats (n = 4; no tumor and no irradiation), to eval-
uate the possible long-term side effects at different times. In all cases, the rats were terminally anaesthetised for 
brain fixation by the intracardiac perfusion of a fixative solution (formalin zinc). The brains were then removed, 
fixed in the fixative solution, and embedded in paraffin; 4-μm-thick sections were cut and stained in haematoxy-
lin and eosin (HE) for the histopathological (double-blinded) analysis, carried out by ECVP (European College 
of Veterinary Pathologists) board certified pathologist. Immunohistochemistry analysis was performed to assess 
the networks and cell morphologies of microglia (anti-Iba-1 antibody, Wako Chemicals, dilution: 1:500) and 
astrocytes (anti-GFAP antibody, Sigma-Aldrich, dilution: 1:500). Astrocyte and microglial cell morphology are 
indeed directly linked to their physiological state35. These specific immunohistochemistry analyses allow detec-
tion of cell processes, i.e. visualization of the cell organization in space. Neuroinflammation is characterized by 
an activation of microglial cells: proliferation, thickening and shortening of the cell processes. Destruction of 
the neuropil and nervous tissue lead to an activation of astrocytes: proliferation, increase number and thickness 
of their cell processes. Ever increasing evidence support the hypothesis that late radiation-induced brain injury, 
including cognitive impairment, is driven by acute and chronic oxidative stress and inflammatory responses36. 
Table 2 summarizes the study groups and the corresponding follow-up.
Results
This section reports on the tumor control effectiveness of pMBRT as well as on the long-term side effects of irra-
diated rats.
Tumor control effectiveness evaluation. Figure 2 shows the survival curves of tumor bearing rats. The 
two curves showed to be statistically significantly different (p < 0.0001).
The mean survival time of the controls was 18 days in contrast to 32.5 days for the irradiated tumour-bearing 
animals. Two irradiated animals (number 10 and 11 in Tables 1 and 2) lived for the entire duration of the study and 
were then censored. Tumour sterilisation in these two long-term survivals was confirmed by the histology. It should 
be stressed that tumour eradication was achieved even with a highly heterogeneous dose distribution deposited in 
one fraction. In contrast, standard radiotherapy uses a homogeneous dose coverage of the target with the aim of 
depositing a lethal dose in every tumour cell. The prescribed dose is mostly deposited in several fractions.
Non-irradiated tumour-bearing rats displayed large gliomas at the moment of the sacrifice, sometimes with 
peripheral necrosis and hyperplasia/activation of microglial cells in the tumour as well as at the periphery. The 
pMBRT-irradiated rats who had to be sacrificed before 3 months after irradiation due to symptoms of tumour 
growth, presented very large gliomas and multifocal necrotic foci in the tumour and brain tissue at the periphery, 
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associated with an activation/hyperplasia of microglial cells. See Figs 3 and 4. In brain tumor and brain metasta-
sis, microglial cells and macrophages are recruited either within or near the tumor masses. Some works suggests 
that they might play an important role in brain tumor progression35.
Concerning the long-term survivals neither substantial damage nor tumor presence were observed in the MRI 
images nor in the histopathological analysis. Only minimal lesions, as small clusters of astrocyte and microglial 
cell activation (minimal neuroinflammation) were found. See Figs 4 and 5.
Figure 2. Survival curves for the controls (n = 7) versus pMBRT irradiated tumor-bearing rats (n = 9). pMBRT 
significantly increases tumor control. Additionally, a 22% of long-term survivals were obtained.
Study groups Sacrificed MRI Histology
Tumor bearing- rats, non-irradiated 
controls (n = 7) When endpoints reached No All
Tumor bearing- rats, pMBRT (n = 9) When endpoints reached or at the end of the study (6 months)
10 days after irradiation (n = 5) 
Long-term survivals (n = 2/9) All
Normal rats, pMBRT (n = 9) If endpoints reached or at the end of study: 6 months (n = 5) 12 months (n = 4) 6 months (n = 5) 12 months (n = 4) All
Normal rats, controls (n = 4) At the end of study No All
Table 2. Study groups and follow-up.
Figure 3. MRI evaluation at short-term. MRI images of two irradiated tumour-bearing rats taken 10 days after 
treatment. Upper row: T2w images. Lower row: T1w images 8 min after Gd injection. A large tumour in the 
right hemisphere is testified by a mass deforming the brain structures in T2w and a large area of blood barrier 
breakdown in T1w.
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Normal rats’ irradiations: evaluation of long-term side effects on normal tissues. The irradiated 
normal rats gained weight normally. No external clinical symptoms were noted. No skin damage was developed. 
A reversible epilation in the minibeam path was observed.
Six months after irradiation 5 irradiated normal animals were imaged and compared to the healthy controls. 
No damage was observed, no significant differences with the non-irradiated controls were found. See Fig. 6.
The histopathological analysis performed 6 months after irradiation revealed only minimal lesions: rare foci of 
microglial cell and astrocyte activation. No significant necrosis nor neuropil destruction were observed. See figure 4.
Figure 4. Histology. pMBRT irradiation protocol: strong impact on glioma but low impact on the normal 
brain tissue. (A–D) Without irradiation, rats displayed large gliomas (A), sometimes with peripheral necrosis 
(A and B, Δ) and proliferation/activation of microglial cells (thickening and shortening of their cell processes) 
in the tumor as well as at the periphery (C). In the necrotic areas, activation of astrocytes (proliferation and 
hypertrophy of cell body and processes: astrogliosis) was detected (D). (E–H) After pMBRT, for rats who had to 
be sacrificed at an early stage (less than 3 months), multifocal necrotic foci could be detected in the tumor (E–G, 
star) and brain tissue at the periphery, associated with a proliferation/hyperplasia of microglial cells (G) and 
astrocytes (H). (I–L) Long-term consequences of pMBRT were minimal on the brain tissue. Almost no lesion 
was indeed detected (in HE: I,J), except rare activated microglial cells (K, arrowheads), and astrocytes (L; left 
panel normal, right panel cluster of activated astrocytes). (M–P) 6 Months after irradiation, almost no lesion 
was detected in irradiated normal rats (M,N) except rare foci of microglial cell (O, arrowheads) and astrocyte 
(P; left panel normal, right panel cluster of activated astrocytes) activation. (Q–T) 12 Months after irradiation, 
the profile was similar as after 6 months, i.e. almost no lesion (Q) except moderate microglial cell hyperplasia 
(S) or foci of activation, associated with focal calcifications (R, arrow) in 2 rats. No astrogliosis was detected (T). 
(U–X) Control rats (no irradiation and no tumor) did not display any histological lesion (only one rat displayed 
small, randomly distributed calcification foci, data not shown). (A,B,E,F,I,J, M,N,Q,R,U,V) HE staining; 
(C,G,K,N,R,V) Iba1 immunohistochemistry to assess microglial cell density and morphology; (D,H,L,P,T,X) 
GFAP immunohistochemistry to assess astrocyte density and morphology.
www.nature.com/scientificreports/
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In the 4 rats that were followed up for one year, the profile was similar to the group sacrificed at 6 months, 
i.e. no visible lesion in the MRI analysis (see Fig. 7) and almost no lesion detected in the histological evaluation 
(except rare foci of microglial cell and astrocyte activation and neuropil mineralisation). No necrosis, neuropil 
destruction, or astrogliosis were observed (Fig. 4).
Discussion
Human glioblastoma multiforme is one of the most aggressive tumours with a median survival of 7–15 months 
from the time of diagnosis. The gold standard management of GBM, tumour resection followed by radiotherapy 
and chemotherapy (typically temozolomide), is limited in efficacy due to high rates of recurrence, overall resist-
ance to therapy, and devastating side effects37. Therefore, finding alternative efficient solutions is of utmost impor-
tance. This work is the first evaluation of the increase in therapeutic index provided by pMBRT in the treatment of 
high-grade gliomas with very heterogeneous dose distributions. Whole brain irradiations excluding the olfactory 
Figure 5. MRI evaluation of long-term survivals. Upper row: T2w (left), T1w before (center) and 8 min after 
Gd injection (right) images of one of the long-term survivals. No substantial damage was observed with the 
exception of a scar in the tumor injection site. No tumor presence was observed.
Figure 6. MRI evaluation of normal rats. Comparison of the MRI images acquired at 6 months after irradiation 
for one of the irradiated animals (upper row) versus one of the controls (lower row). T2w images (A,F), RARE-
T1w images before (B,G) and after 8 min Gd injection (D,J) and FLASH-T1w images before (C,H) and after 
(E,I) Gd injection are shown. No tissue damage is observed and no significant difference was found between 
irradiated and control animals.
Figure 7. MRI acquisition of irradiated normal rats after one year of follow up. T2w (left) and T1w-RARE 
images before (center) and 8 minutes (right) after Gd injection. No substantial lesions are observed.
www.nature.com/scientificreports/
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bulb were performed with peak doses of 70 Gy at 1 cm-depth, corresponding to a mean dose of 30 Gy. The spacing 
between the beams was 3.2 mm. Thus, large areas of the tumour receive (low) non-lethal doses. No comparison 
with conventional (seamless) PT has been performed since such high mean doses would not be tolerated27. In our 
previous work27 severe damage, including radionecrosis was observed in the group of rats that received 25 Gy in 
conventional proton therapy. These results are coherent with some other studies using X-rays38. To the best of our 
knowledge there are not in vivo preclinical evaluations of the effects on the brain of conventional temporally frac-
tionated schemes in proton therapy to compare with. One of the main reasons is the impossibility of employing 
several hours of beamtime of a clinical proton beamline daily. The availability of experimental proton beamlines 
would make it feasible. However, in brain patients, treated with conventional several fractions-schemes in proton 
therapy, the percentage of induced radionecrosis is high and it can reach 50% in pediatric patients39.
pMBRT has shown a very significant effectiveness of tumour control in RG2 glioma bearing rats, achieving as 
well a 22% of long-term survivals, free of tumour. And that, without some of substantial side effects, such as radi-
onecrosis, that would have been observed with standard PT, already at lower doses27,39, thus opening the possibil-
ity for even more aggressive irradiation schemes. Further evaluations on neurogenesis integrity and behavioural 
tests to discard any cognitive impairment will be performed. The optimization of the irradiation parameters, such 
as the beam spacing or the dose, might further increase the number of curations in pMBRT.
Long-term survivals were also obtained in gliosarcoma (9 L) bearing rats treated with very heterogeneous 
dose distributions in microbeam radiation therapy (MRT)14,40,41. A direct comparison with this study is not pos-
sible due to the different cell lines employed. However, this work shows that similar results could obtained with 
pMBRT using a dose 4 times lower than in MRT. Enormous doses of more than 300 Gy in the peaks, around 
18 Gy valleys and 120 Gy mean dose, are needed in MRT to obtain a significant tumour control. The fact of using 
supra-millimetre minibeams (1.1 mm at 1-cm depth) removes the need of very high dose rates to avoid the beam 
smearing of cardiosynchronous pulsations in MRT42. In addition, the implementation and dosimetry are tech-
nically easier and much less error prone when thick beams are used. Finally, in contrast to MRT, our studies in 
pMBRT are directly performed at a clinical centre, which makes the transfer to potential clinical trials a direct 
one.
It is worth noting that tumour control and tumour sterilization were achieved with such heterogeneous dose 
distribution in one fraction. In contrast, the classical paradigm of RT requires the deposition of a lethal dose in 
every tumour cell for tumour ablation. The dose is usually delivered in several fractions to reduce normal tissue 
toxicity and favour tumour re-oxygenation.
Our hypothesis to explain our results with such distinct dose delivery is the participation of some non-targeted 
effects. Indeed, temporal schemes using very high-dose radiation in one fraction have been reported to trans-
form the immunosuppressive tumour microenvironment resulting in an intense CD8 T-cell tumour infiltrate14,43. 
Some hints of the participation of cell signalling effects15,16 have been reported in other spatially fractionated 
techniques. Another possible player might appear to be the preferential effect on the tumoral versus normal 
vasculature15,17. The investigation of the possible participation of all those phenomena requires a comprehensive 
approach, and it is out of the scope of this work.
The study on normal rats confirms a remarkable tissue-sparing effect of 70-Gy supra-millimetre minibeams 
and relatively low PVDR (around 6.5). These results have important implications for potential clinical trials, 
since it opens the door for future implementations with pencil beam scanning systems (millimetre-size beams). 
The significant increase in tumour control effectiveness and the reduced neurotoxicity observed in the irradiated 
normal rats confirms the widening of the therapeutic window. Moreover, the fact that large areas (or even whole 
brain) could be irradiated without significant side effects, could allow overcoming one of the major difficulties to 
be faced in gliomas treatment: its infiltrative nature. One of the key problems when treating patients with malig-
nant gliomas is that, despite being able to remove the major bulk of the tumor through neurosurgery, it is known 
that malignant tumor cells have already spread throughout the brain and even extensive resections will not cure 
the patient.
Finally, the results of this study show that pMBRT could offer a completely innovative and promising way of 
using protons for therapy. Moreover, the lack of need of a homogeneous coverage of the target to achieve tumour 
control along with the reduced toxicity in the surrounding normal tissues diminish the requirements in terms 
of positioning and ballistics precision. This could optimize the patient workflow, reducing proton therapy costs 
consequently.
Data Availability Statement
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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